Global Multiple Sclerosis Drugs Companies

Q: What is the key market trend for Global Multiple Sclerosis Drugs Market?

Development of Disease-Modifying Therapies: Disease-modifying therapies (DMTs) play a critical role in managing MS by reducing relapse rates, delaying disease progression, and preserving neurological function. The market has witnessed the development of newer and more effective DMTs, such as monoclonal antibodies and oral therapies, with improved efficacy and safety profiles. The focus on developing DMTs continues to drive the market, providing patients with more options for disease management.

Global Multiple Sclerosis Drugs Market Competitive Landscape

Multiple Sclerosis Drugs Market Top Player’s Company Profiles

Biogen Inc. (United States)

Roche Holdings AG (Switzerland)

Novartis AG (Switzerland)

Sanofi S.A. (France)

Merck & Co., Inc. (United States)

Teva Pharmaceutical Industries Ltd. (Israel)

Bayer AG (Germany)

Pfizer Inc. (United States)

GlaxoSmithKline plc (United Kingdom)

AbbVie Inc. (United States)

Johnson & Johnson Services, Inc. (United States)

Celgene Corporation (United States)

Bristol-Myers Squibb Company (United States)

Mitsubishi Tanabe Pharma Corporation (Japan)

Biogen Idec International GmbH (Switzerland)

Genzyme Corporation (United States)

F. Hoffmann-La Roche Ltd (Switzerland)

Merck KGaA (Germany)

Mylan N.V. (United States)

Eisai Co., Ltd. (Japan)

Takeda Pharmaceutical Company Limited (Japan)

Ipsen (France)

Multiple Sclerosis Drugs Market

FAQs

Global Multiple Sclerosis Drugs Market size was valued at USD 24.64 Billion in 2022 and is poised to grow from USD 25.40 Billion in 2023 to USD 32.43 Billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).

Key manufacturers are involved in initiatives such as new product development in an attempt to sustain market dominance. Companies are also actively involved in collaborating with other drug manufacturers for the co-development of drugs. This initiative is expected to help manufacturers strengthen their product portfolio in the multiple sclerosis therapeutics market. 'Biogen Inc. (United States)', 'Roche Holdings AG (Switzerland)', 'Novartis AG (Switzerland)', 'Sanofi S.A. (France)', 'Merck & Co., Inc. (United States)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Bayer AG (Germany)', 'Pfizer Inc. (United States)', 'GlaxoSmithKline plc (United Kingdom)', 'AbbVie Inc. (United States)', 'Johnson & Johnson Services, Inc. (United States)', 'Celgene Corporation (United States)', 'Bristol-Myers Squibb Company (United States)', 'Mitsubishi Tanabe Pharma Corporation (Japan)', 'Biogen Idec International GmbH (Switzerland)', 'Genzyme Corporation (United States)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Merck KGaA (Germany)', 'Mylan N.V. (United States)', 'Eisai Co., Ltd. (Japan)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Ipsen (France)'

Existing drugs used in the treatment of multiple sclerosis are often tested for additional indications and expanded usage. For example, some drugs initially approved for relapsing-remitting MS have received approvals for secondary progressive MS or clinically isolated syndrome. The expanded indications widen the patient population that can benefit from these drugs, leading to increased sales and market growth.

Development of Disease-Modifying Therapies : Disease-modifying therapies (DMTs) play a critical role in managing MS by reducing relapse rates, delaying disease progression, and preserving neurological function. The market has witnessed the development of newer and more effective DMTs, such as monoclonal antibodies and oral therapies, with improved efficacy and safety profiles. The focus on developing DMTs continues to drive the market, providing patients with more options for disease management.

Due to the significant presence of major players and the rising prevalence of multiple sclerosis, North America currently controls the majority of the global market for multiple sclerosis. Companies like Novartis AG, Sanofi SA, and Biogen have established significant market positions in the United States and are consistently putting more emphasis on launching new medications. According to the National Multiple Sclerosis Society, Canada has the highest MS prevalence rate in the world (291 per 100,000). According to the National MS Society, there are 1 million or so MS patients in the United States.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral) - Industry Forecast 2024-2031

Global Multiple Sclerosis Drugs Market Competitive Landscape

Global Multiple Sclerosis Drugs Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral) - Industry Forecast 2024-2031

Global Multiple Sclerosis Drugs Market Competitive Landscape

Global Multiple Sclerosis Drugs Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Multiple Sclerosis Drugs Market?

Who are the key vendors in the Global Multiple Sclerosis Drugs Market?

What is the key driver of Global Multiple Sclerosis Drugs Market?

What is the key market trend for Global Multiple Sclerosis Drugs Market?

Which region accounted for the largest share in Global Multiple Sclerosis Drugs Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300